Compugen (CGEN) Issues Letter to Shareholders

Go back to Compugen (CGEN) Issues Letter to Shareholders

Compugen Letter to Shareholders

September 22, 2022 7:00 AM UTC

HOLON, Israel, Sept. 22, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, is pleased to issue the following letter to shareholders:

Dear Shareholders,

As we approach the Jewish New Year, I am taking this opportunity to provide you with an update of our progress since the publication of the second quarter 2022 financial... More